Editas shelves lead asset after proof-of-concept data widdles down likely patient population

When Editas CEO Gilmore O’Neill took the reins of the CRISPR gene editing company, he acknowledged that one of the draws was the sizeable cash runway available. | Editas is struggling to keep pace with its counterparts in the gene-editing field, announcing its lead asset would be shelved while it searches for a partner. Updated data from the company’s phase 1/2 trial for EDIT-101 found that it was most effective in a very small population with little market upside.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source